Compare · ARGX vs MAZE
ARGX vs MAZE
Side-by-side comparison of argenx SE (ARGX) and Maze Therapeutics Inc. (MAZE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and MAZE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $62.50B, about 42.7x MAZE ($1.46B).
- Over the past year, ARGX is up 31.1% and MAZE is up 51.2% - MAZE leads by 20.1 points.
- MAZE has been more active in the news (15 items in the past 4 weeks vs 10 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 7 for MAZE).
- Company
- argenx SE
- Maze Therapeutics Inc.
- Price
- $1005.57-0.21%
- $24.60-6.71%
- Market cap
- $62.50B
- $1.46B
- 1M return
- +16.08%
- -8.96%
- 1Y return
- +31.06%
- +51.17%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2025
- News (4w)
- 10
- 15
- Recent ratings
- 25
- 7
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Completes Acquisition of Forte Biosciences, Inc.
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Latest MAZE
- President, R&D & CMO Bernstein Harold sold $254,502 worth of shares (9,705 units at $26.22) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- GC and Corp. Secretary Courtney Phillips converted options into 11,000 shares (SEC Form 4)
- Chief Executive Officer Coloma Jason V sold $906,999 worth of shares (34,501 units at $26.29) as part of a pre-agreed trading plan and converted options into 50,000 shares (SEC Form 4)
- CSBO Dandekar Atul converted options into 12,500 shares, increasing direct ownership by 48% to 38,750 units (SEC Form 4)
- President, R&D & CMO Bernstein Harold exercised 36,141 shares at a strike of $4.65 and sold $425,512 worth of shares (16,141 units at $26.36) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Maze Therapeutics Inc.
- SEC Form 144 filed by Maze Therapeutics Inc.
- Maze Therapeutics to Participate in Three Upcoming Investor Conferences
- SEC Form 144 filed by Maze Therapeutics Inc.
- CSBO Dandekar Atul sold $206,824 worth of shares (7,500 units at $27.58) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $10.42 (SEC Form 4)